Tae Han, PhD

Tae is an entrepreneur, investor, and drug developer.  He has extensive experience across multiple drug modalities and therapeutic areas including oncology, neuroscience, cardiovascular, and metabolic.  Since starting his career at Merck, he has held positions of increasing responsibility at multiple companies at the forefront of science and medicine (Seattle Genetics/Seagen, Stemcentrx, AbbVie, and Amphivena).  Tae co-founded ProfoundBio (acquired by Genmab for $1.8B in May), where he served in multiple roles, including board member, President, Chief Operating Officer, and Chief Strategy Officer.  Tae has a B.S. in Chemical Engineering from the University of Washington and a Ph.D. in Chemical and Biomolecular Engineering from UCLA.  He also received a NIH postdoctoral training grant to study Cardiology at UCLA.